Pharvaris Reports Positive Phase 3 CHAPTER-3 Data for Deucrictibant XR
ZUG, Switzerland — September 8, 2026 Pharvaris announced positive topline results from the CHAPTER-3 pivotal Phase 3 study evaluating...
Regulatory Submission
Advertisement
Kaneka Advances Ubiquinol Quality with New Testing Phase
PASADENA, Texas, July 15, 2026 Kaneka Nutrients has announced the third phase of its independent Ubiquinol authenticity testing program,...
Orasis Files Australia NDA for BESKA Eye Drops
PONTE VEDRA, Fla., July 15, 2026 Orasis Pharmaceuticals has reached an important international regulatory milestone with the submission of...
Bavarian Nordic Seeks Brazil Approval for Chikungunya Vaccine
COPENHAGEN, Denmark, July 13, 2026 Bavarian Nordic announced that its Brazilian partner Eurofarma has submitted a marketing authorization application...
Keenova Reports Positive Phase 3 Results for XIAFLEX
DUBLIN, Ireland, July 8, 2026 Keenova Therapeutics plc has announced positive Phase 3 clinical trial results for XIAFLEX® (collagenase...
Advertisements
IDEAYA Updates Darovasertib Phase 2/3 Trial Timeline
South San Francisco, California, USA | March 22, 2026 IDEAYA Biosciences has announced updated guidance on the anticipated topline...
NanoViricides Files FDA Orphan Drug Bid for NV-387
Shelton, Connecticut — February 10, 2026: NanoViricides, Inc., a clinical-stage antiviral nanomedicine company, announced the filing of an Orphan...
Lilly’s Oral GLP-1 Orforglipron Delivers Strong Phase 3 Results in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 — Eli Lilly and Company (NYSE: LLY) announced positive topline results from two pivotal Phase...
Sanofi’s Wayrilz Approved in the U.S. as First BTK Inhibitor for Immune Thrombocytopenia
Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for...
Advertisement
